Results 41 to 50 of about 5,649 (188)

Real-world evidence in gynecologic cancers presented at key oncology conferences in the United States: Distribution and factors related to high-tier acceptance.

PLoS ONE
PurposeTo describe the distribution, trends, and characteristics of types of real-world evidence (RWE) abstracts presented at key oncology congresses.MethodsData on gynecologic cancers (cervical, ovarian, endometrial, and multiple gynecologic/other) were
Elizabeth A Szamreta, Mansi Modi, Ramu Periyasamy, Bhavani Yamsani, Pattabhi Machiraju, Neetu Menghani, Matthew Monberg   +6 more
doaj   +1 more source

The Increased National Threat of Domestic, Right-Wing Extremist Terrorism

The Journal of Intelligence, Conflict and Warfare, 2018
Right-wing extremism (RWE) presents a national Canadian threat, requiring research and Countering Violent Extremism (CVE) programming, which Canadian security and intelligence is arguably failing to recognize and address.
Caitlin Manz
doaj   +1 more source

Maintaining patient registries, on the basis of which regulatory authorities can make decisions regarding medicines

Реальная клиническая практика: данные и доказательства, 2023
The use of data and evidence from real clinical practice (RWD / RWE) is becoming more and more relevant to the healthcare system when making critical decisions in the field of drug circulation regulation, as well as making decisions on the inclusion or ...
A. V. Ivanov, V. N. Semykin
doaj   +1 more source

Advancing Pharmacoequity Globally: Reflections from the ASCPT Development, Regulatory, and Outcomes Network

Clinical Pharmacology &Therapeutics, EarlyView.
ASCPT has a mission to advance clinical pharmacology and translational sciences to reduce health disparities. The development, regulatory, and outcomes (DRO) network within ASCPT strives to advance pharmacoequity globally. Pharmacoequity, coined by Utibe Essien (2021), is the principle that all individuals, regardless of race, ethnicity, geography, or ...
Priya Jayachandran, Mayur K. Ladumor, Georgios Vlasakakis, Andrew Riselli, Katarina V. Ilic, Rob C. van Wijk, Mohamed Elmeliegy, Jatinder Kaur Mukker, Aarti Sawant‐Basak, Tao Long, Juyao Dong, Noha Rayad, Tao Zhang, on behalf of the DRO Network   +13 more
wiley   +1 more source

Review of data sources used in real-world traumatology and orthopedic

Реальная клиническая практика: данные и доказательства, 2023
Real-world data (RWD) play an increasingly important role in traumatology and orthopedics, as evidenced by the rapidly growing number of publications using registry, administrative, and other databases.
I. U. Zolotukhina, A. R. Kasimova
doaj   +1 more source

Implementation of OMOP and ConcePTION Common Data Models in CPRD GOLD: Risk of Bleeding and Cardiovascular Outcomes From Anticoagulant Use

Clinical Pharmacology &Therapeutics, EarlyView.
The impact of the choice of common data model (CDM) approach on the study results in a real‐world evidence (RWE) study is unknown. We aimed to determine potential differences in the results of an RWE study when data were mapped to two different CDMs, ConcePTION and OMOP. With the same instance of CPRD GOLD, data were mapped to both CDMs. Using the same
Nicholas B. Hunt, Patrick Souverein, Marloes Bazelier, Nicola Barclay, Antonella Delmestri, Miriam Sturkenboom, Daniel Prieto‐Alhambra, Helga Gardarsdottir, Olaf Klungel   +8 more
wiley   +1 more source

Twórcy polscy w RWE

Archiwum Emigracji, 2009
Rec.: Violetta Wejs-Milewska, Radio Wolna Europa na emigracyjnych szlakach pisarzy.
openaire   +4 more sources

RWE in Europe Paper IV: Engaging pharma in the RWE Roadmap

, 2017
This paper summarises discussions held at the fourth round-table style meeting with a group of expert stakeholders with experience in specialist disease areas and commissioning of care plus prior experience in the field of real world evidence (RWE). The aim of these meetings was to gain an understanding of the use of RWE across Europe and to develop a ...
Gill, Jennifer, Kanavos, Panos, d'Angela, Daniela, Berger, Karin, Dank, Magdolna, Duncombe, Robert, Fink-Wagner, Antje-Henriette, Hutton, John, Kossler, Ingrid, Podrazilova, Katerina, Thomas, Michael   +10 more
openaire   +2 more sources

Effectiveness and safety of ustekinumab in pediatric Crohn's disease: Results of the REALITI study

Journal of Pediatric Gastroenterology and Nutrition, EarlyView.
Abstract Objectives Few approved treatments exist for children with Crohn's disease (CD). The REALITI study retrospectively assessed the effectiveness and safety of ustekinumab in real‐world clinical settings for children with CD. Methods Data were collected from the prospective ImproveCareNow (ICN) registry for pediatric patients (≥ 2 to <18 years old)
Steven J. Steiner, Jeremy Adler, Shehzad A. Saeed, Richard S. Strauss, Kristin M. Howe, Anna Sheahan, Renping Zhang, Kimberly R. Keihn, Katharine Harrow, Kelly K. Olano, David A. Evans, Kim Hung Lo, Nanhua Zhang, Lilianne Kim, Richard B. Colletti, Sheri Volger, for the ImproveCareNow Learning Health Network, Sabina Ali, Rana Ammoury, Keren L. Appel, Travis Ayers, Howard Baron, Julie Bass, Rachel Bensen, Erica J. Brenner, José Cabrera, Mallory Chavannes, J Fernando del Rosario, Jill Dorsey, Dana M. H. Dykes, Dawn R. Ebach, Bhaskar Gurram, Dyer Heintz, Leslie M. Higuchi, Edward J. Hoffenberg, Jeannie S. Huang, Esther Jacobowitz Israel, Traci W. Jester, Ian Kang, Ian Leibowitz, Tiffany Linville, Ross M. Maltz, Craig A. McKinney, Lybil B. Mendoza Alvarez, Phillip Minar, Tina Morhardt, Alisa J Muñiz Crim, Barbara Joanna Niklinska‐Schirtz, Daniel M. O'Connell, Helen Pappa, Brad Pasternak, Trusha Patel, Meryl K. Perlman, Kelly C. Sandberg, Marc E. Schaefer, Robbyn E. Sockolow, David L. Suskind, Gitit Tomer, Jeanne Tung, Amanda A. Wenzel, Denise D. Young   +60 more
wiley   +1 more source

Real‐World, Prospective, Multicenter Outcomes to Brodalumab Treatment in Patients With Moderate‐to‐Severe Psoriasis in Greece (The RESOLVE Study)

JEADV Clinical Practice, EarlyView.
RESOLVE was a prospective, real‐world study in patients with moderate‐to‐severe psoriasis treated with brodalumab. At Week 12, 76.4% achieved PASI ≤ 3, 53.5% PASI100, and 71.5%/54.2% achieved sPGA0/1 and sPGA 0, respectively. At Week 52, 96.1% achieved sPGA success (clear/almost clear). Furthermore, at Week 52, mean DLQI scores decreased by 12.6 ± 6.2,
Electra Nicolaidou, Pantelis Panagakis, Dimitrios Xekardakis, Natalia Rompoti, Marina Papoutsaki, Ioanna Lefaki, Kanella Kalapothakou, Despina Exadactylou, Athanasios Chaniotis, Vasiliki Chasapi, Alexander Stratigos   +10 more
wiley   +1 more source